Search clinical trials for: Atezolizumab Placebo

Total 54124 results

Gruppo Oncologico Italiano di Ricerca Clinica

Recruiting

Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso) (AtezoMeso)

Mesotheliomas Pleural

Italy
University of Southern California
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditions

United States
Intergroupe Francophone de Cancerologie Thoracique
Roche Pharma AG; GFPC

Completed

Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC (CLINATEZO)

Small Cell Lung Cancer

France
Yonsei University

Not yet recruiting

Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer (SKYROCKET)

Non-small Cell Lung Cancer

Korea, Republic of
Nykode Therapeutics ASA
Roche Pharma AG; GOG Foundation

Not yet recruiting

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Cervical Cancer | HPV-Related Malignancy | HPV-Related Cervical Carcinoma
Corvus Pharmaceuticals, Inc.
Genentech, Inc.

Completed

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Renal Cell Cancer | Metastatic Castration Resistant Prostate Cancer

United States, Canada, Australia
Incyte Corporation
Hoffmann-La Roche; Genentech, Inc.

Terminated

A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)

UC (Urothelial Cancer) | NSCLC (Non-small Cell Lung Carcinoma)

United States
First Affiliated Hospital of Zhejiang University
Hoffmann-La Roche; Geneplus-Beijing Co. Ltd.

Unknown

The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients

Non-Small Cell Lung Cancer

China
Chonnam National University Hospital
Roche Pharma AG

Completed

Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY] (BUDDY)

Lung Neoplasm Malignant

Korea, Republic of
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

United States
The Netherlands Cancer Institute
Roche Pharma AG

Completed

Carboplatin-cyclophosphamide Combined With Atezolizumab (PROLOG)

Breast Cancer | Ovarian Cancer | Cervix Cancer | Endometrial Cancer

Netherlands
Yale University

Terminated

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

Asymptomatic Myeloma

United States
Seoul National University Hospital

Unknown

The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer

Urothelial Carcinoma
Hunan Province Tumor Hospital

Completed

Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Completed

Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

China
University Medical Center Groningen
Hoffmann-La Roche; Amsterdam UMC, location VUmc; Stichting Hemato-Oncologie voor...

Withdrawn

Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Netherlands
University Medical Center Groningen

Terminated

89Zr-atezolizumab PET Scan and Lobular Breast Cancer (ImaGelato)

Lobular Metastatic Breast Cancer

Netherlands
Immune Design
Genentech, Inc.

Terminated

Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)

Sarcoma | Myxoid/Round Cell Liposarcoma | Liposarcoma | Synovial Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma

United States
Pieris Pharmaceuticals, Inc.

Unknown

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Bladder Cancer | HER2-positive Solid Tumor

United States
Celldex Therapeutics
Genentech, Inc.

Terminated

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Melanoma | Neoplasms | Neoplasms by Histologic Type | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Kidney Diseases | Urologic Diseases | Head and Neck Cancer | Bladder Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Clear-cell Metastatic Renal Cell Carcinoma

United States
National Taiwan University Hospital
Roche Pharma AG; Ipsen

Recruiting

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Cancer | Metastatic Cancer | Squamous Cell Carcinoma

Taiwan
Clovis Oncology, Inc.
Genentech, Inc.

Terminated

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Non-small Cell Lung Cancer

United States
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (SKYSCRAPER-07)

Esophageal Squamous Cell Carcinoma

United States, France, Spain, Australia, Korea, Republic of, Argentina, Belgium, China, Portugal, Taiwan, Japan, Germany, Poland, Thailand, United Kingdom, Switzerland, Turkey, Russian Federation, Morocco, Greece, Italy, New Zealand, South Africa and more
Hunan Province Tumor Hospital

Completed

Severe Adverse Events Biomarkers Investigation on Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Cancer

China
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Terminated

Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma

Lymphoma

United States
Hoffmann-La Roche

Completed

A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Neoplasms

Belgium, France, Spain
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Melanoma

United States, Korea, Republic of, United Kingdom, Australia, France, Belgium, Italy, Portugal, Spain, Brazil, Canada, Russian Federation, Germany, New Zealand, Israel, Poland, Greece, Austria, Hungary, Netherlands
Spanish Oncology Genito-Urinary Group
Roche Farma, S.A; Dynamic Science S.L.

Active, not recruiting

Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer

Bladder Cancer

Spain
Hoffmann-La Roche

Completed

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131)

Triple-Negative Breast Cancer

France, Canada, Israel, Italy, Argentina, Brazil, China, Croatia, Germany, Greece, Slovakia, Turkey, Saudi Arabia, Japan, India, Spain, United States, Czechia, Romania, United Kingdom, Morocco, South Africa, Vietnam, Russian Federation
Centre Leon Berard
Roche Pharma AG

Recruiting

Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy (RT-Immune)

Sarcoma,Soft Tissue

France, United Kingdom
University of Michigan Rogel Cancer Center

Withdrawn

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Prostate Cancer

United States
Genentech, Inc.

Approved for marketing

An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy

Urothelial Carcinoma

United States
The Netherlands Cancer Institute
Hoffmann-La Roche

Completed

PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study (PERICLES)

Penile Cancer

Netherlands
Hospices Civils de Lyon

Recruiting

Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (IMMUNOGAST)

Gastric Adenocarcinoma | Metastatic Gastric Cancer | Advanced Gastric Carcinoma | Metastatic Adenocarcinoma

France
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Korea, Republic of, Canada, Australia, Russian Federation, United Kingdom, Belgium, Brazil, China, France, Italy, Portugal, Spain, Japan, India, Thailand, Ukraine, Taiwan, Poland, Turkey, Hungary, South Africa, Germany
Grupo Espanol Multidisciplinario del Cancer Digestivo
Hoffmann-La Roche

Recruiting

Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS) (TIRANUS)

Squamous Cell Carcinoma of the Anal Canal

Spain
Hoffmann-La Roche

Completed

A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors

Solid Tumors

Hungary, United States, Korea, Republic of, Belgium, Germany, United Kingdom
University of Arizona

Recruiting

Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer

Pancreatic Cancer | Metastatic Pancreatic Cancer

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer (PICASSO)

Small Cell Lung Cancer

Italy
Cedars-Sinai Medical Center
Genentech, Inc.

Recruiting

Atezolizumab for Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States
Memorial Sloan Kettering Cancer Center
Genentech, Inc.

Terminated

Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

United States
Shanghai Zhongshan Hospital
Fudan University; Shanghai Jiao Tong University School of Medicine

Completed

B7-Family Score in Urothelial Carcinoma

Urothelial Carcinoma
Lokon Pharma AB
Precision Oncology LLC

Completed

A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma

Malignant Melanoma

Sweden, United States
University Medical Center Groningen

Recruiting

Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors (TIRACAN)

Melanoma | Head and Neck Neoplasms | MSI-H Cancer

Netherlands
Hoffmann-La Roche

Terminated

A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce) (Announce)

Urothelial Carcinoma

Germany
Institut Bergonié
Roche Pharma AG; National Cancer Institute, France; Seven and Eight Biopharmaceuticals...

Recruiting

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors (AGADIR)

Melanoma | Pancreatic Cancer | Non Small Cell Lung Cancer | Bladder Cancer | Triple Negative Breast Cancer | Solid Tumor, Adult | Virus-associated Tumors

France
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma (SKYSCRAPER-08)

Esophageal Cancer

Korea, Republic of, China, Hong Kong, Thailand, Taiwan
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors (SKYSCRAPER-11)

PD-L1-selected Solid Tumors

Korea, Republic of, United States, Spain, Taiwan, Turkey, Greece, Canada, Croatia, Serbia, Mexico, Cyprus, Georgia
Hoffmann-La Roche

Recruiting

A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (IMvigor011)

Muscle-invasive Bladder Cancer

Belgium, Korea, Republic of, Japan, Brazil, China, United States, Singapore, France, United Kingdom, Canada, Greece, Israel, Italy, Spain, Turkey, Russian Federation, Ukraine, Czechia, Colombia, Hong Kong, Argentina, Germany, Ireland, Polan... and more
Galecto Biotech AB
Hoffmann-La Roche; Linical Europe GmbH

Active, not recruiting

A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).

Non-Small Cell Lung Cancer

Spain, Poland, France

Search clinical trials for: Atezolizumab Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations